Table 4.
Performance of PI-RADS v2 and 1H-MRSI, alone and combined, for the discrimination of high-grade prostate cancer (dominant Gleason pattern ≥ 4) and extraprostatic disease at radical prostatectomy.
| Reader 1 | Reader 2 | |||||
|---|---|---|---|---|---|---|
| Model variables | AUC | 95% CI | AUC | 95% CI | ||
| Dominant Gleason pattern 4 or higher outcome | ||||||
| Overall PI-RADS 2 | 0.65 | 0.49-0.81 | 0.61 | 0.45-0.77 | ||
| 1H MRSI | 0.75 | 0.62-0.87 | 0.70 | 0.55-0.86 | ||
| Overall PI-RADS 2 + 1H MRSI | 0.77 | 0.63-0.91 | 0.70 | 0.53-0.86 | ||
| Pathological stage T3a or higher outcome | ||||||
| Overall PI-RADS 2 | 0.54 | 0.34-0.73 | 0.60 | 0.42-0.78 | ||
| 1H MRSI | 0.61 | 0.43-0.79 | 0.54 | 0.36-0.73 | ||
| Overall PI-RADS 2 + 1H MRSI | 0.55 | 0.34-0.76 | 0.61 | 0.43-0.80 | ||
95% CI, 95% confidence interval.